Journal of Medical Economics

Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R

 

 

Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients

J Med Econ. 2012;15(3):1–10